Deal Library / Pharma BD Deal Intelligence

Takeda Pharmaceutical Company Limited — Pharma Deals

The Pharma Closeout tracks 9 deals, $20.2B in disclosed deal value, 4 with a post-close Outcome Score for Takeda Pharmaceutical Company Limited.

Median Critic Score: 74  ·  Median Outcome Score: 54

Best outcome: Takeda Pharmaceutical Company Limited / Millennium Pharmaceuticals, Inc. (68)  ·  Weakest outcome: Takeda Pharmaceutical Company Limited / ARIAD Pharmaceuticals, Inc. (47)

All 9 deals

• Takeda Pharmaceutical Company Limited / Millennium Pharmaceuticals, Inc. — 2008 · $8.8B · Largely worked — most objectives met.
• Takeda Pharmaceutical Company Limited / Insilico Medicine Inc. — 2026 · $600M · Mixed — partial payoff, real shortfalls.
• Takeda Pharmaceutical Company Limited / TESARO, Inc. — 2017 · $340M · Mixed — partial payoff, real shortfalls.
• Takeda Pharmaceutical Company Limited / ARIAD Pharmaceuticals, Inc. — 2017 · $5.2B · Mixed — partial payoff, real shortfalls.
• Takeda Pharmaceutical Company Limited / Degron Therapeutics Ltd. — 2024 · $1.2B
• Takeda Pharmaceutical Company Limited / AC Immune SA — 2024 · $2.2B
• Takeda Pharmaceutical Company Limited / HUTCHMED (China) Limited — 2023 · $1.1B
• Takeda Pharmaceutical Company Limited / Novavax Inc. — 2021 · $350M
• Takeda Pharmaceutical Company Limited / GammaDelta Therapeutics Limited — 2021 · $350M

← Deal Library  ·  Interactive search  ·  How we score deals